<\/p>\n
\ud83d\udca1 Snel antwoord<\/strong><\/p>\n Etibo<\/strong> is lapatinib 250 mg<\/strong>, een dual HER2\/EGFR tyrosine kinase inhibitor<\/strong> for advanced or metastatic HER2-positive breast cancer<\/strong>. Oral once-daily therapy combined with capecitabine or other regimens, usually after trastuzumab (Herceptin) failure. Significant side effects include diarrhoea, rash, and cardiotoxicity; requires close oncologist supervision and ECG monitoring.<\/p>\n<\/div>\n \ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n Etibo is a branded generic of lapatinib<\/strong> 250 mg, a small-molecule tyrosine kinase inhibitor that targets HER2 (ErbB2)<\/strong> en EGFR (ErbB1)<\/strong>. Lapatinib blocks intracellular signaling downstream of these receptors, halting proliferation of HER2-positive cancer cells. Manufactured by Natco Pharma.<\/p>\n Critical:<\/strong> Lapatinib is an oncology drug used only under specialist supervision. It is not a general women’s health product. Use strictly according to oncologist protocol \u2014 typically after trastuzumab resistance develops.<\/p>\n Zeer vaak voorkomend:<\/strong> diarrhoea (60\u201380%), rash (40\u201360%), nausea, vomiting, fatigue, hand-foot syndrome, palmar-plantar erythrodysesthesia (with capecitabine combo).<\/p>\n Significant:<\/strong> hepatotoxicity<\/strong> (monitor LFTs), cardiotoxicity \/ reduced LVEF<\/strong> (5\u20136%), QT prolongation, interstitial lung disease (rare but serious).<\/p>\n Ernstig:<\/strong> severe liver injury, heart failure, severe skin reactions (Stevens-Johnson), pulmonary toxicity.<\/p>\n Store at room temperature (15\u201330 \u00b0C), away from moisture. Keep in original packaging. Keep out of reach of children.<\/p>\n Advanced\/metastatic HER2-positive breast cancer, typically after trastuzumab (Herceptin) resistance. Not used for early-stage curative therapy.<\/p>\n Food increases lapatinib absorption 4\u20135\u00d7, making dosing unpredictable. Standard is consistent fasting \u2014 1 hour before or after food \u2014 at a fixed time each day.<\/p>\n Common, often grade 1\u20132; manageable with loperamide and hydration. Grade 3+ diarrhoea may require treatment interruption and dose reduction. Report early.<\/p>\n About 5\u20136% of patients have asymptomatic LVEF drops. ECG + echocardiogram at baseline and every 3 months. Usually reversible on dose adjustment or interruption.<\/p>\n Combination lapatinib + trastuzumab is used in specific protocols. Not routine without oncologist supervision.<\/p>\n Effective contraception required during treatment and for 1 week after (teratogenic). Men should use effective contraception during and 3 months after.<\/p>\n HER2+ breast cancer disproportionately affects women (though rarely men get HER2+ breast cancer). Categorisation reflects the population, not a strict clinical cluster.<\/p>\n For second-line HER2+ metastatic disease (after trastuzumab), lapatinib + capecitabine was standard for years. Newer options (T-DM1\/Kadcyla, T-DXd\/Enhertu, tucatinib) have since largely supplanted it in first-world oncology \u2014 lapatinib remains important where newer agents are unavailable.<\/p>\n \u2695\ufe0f Medische disclaimer:<\/strong> De informatie is educatief en vervangt geen medisch advies. Raadpleeg een arts voordat u begint, stopt of een medicatie wijzigt, met name voor kankerbehandeling, hormonale therapie\u00ebn en voorgeschreven producten.<\/p>\n<\/div>\n <\/p>\n Andere oncologische medicijnen die naast dit product wordt aangeboden:<\/p>\n \u2705 Targets cancer cells Etibo contains Lapatinib.<\/p>","protected":false},"featured_media":58016,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223,3502],"product_tag":[4402,4403],"class_list":{"0":"post-58015","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_cat-womens-health","10":"product_tag-etibo","11":"product_tag-lapatinib","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product\/58015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/comments?post=58015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media\/58016"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media?parent=58015"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_brand?post=58015"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_cat?post=58015"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_tag?post=58015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Waarom bestellen bij MedsBase<\/h3>\n
What Is Etibo?<\/strong><\/h2>\n
Genitale herpes (eerste episode):<\/strong><\/h2>\n
\n
Hoe in te nemen<\/strong><\/h2>\n
\n
Bijwerkingen<\/strong><\/h2>\n
Who Should Not Take Etibo<\/strong><\/h2>\n
\n
Geneesmiddelinteracties<\/strong><\/h2>\n
\n
Opslag<\/strong><\/h2>\n
Veelgestelde vragen<\/h2>\n
When is lapatinib used?<\/h3>\n
Why take on empty stomach?<\/h3>\n
How bad is the diarrhoea?<\/h3>\n
Will lapatinib damage my heart?<\/h3>\n
Can I take lapatinib with trastuzumab?<\/h3>\n
What about fertility?<\/h3>\n
Why is this in the Women's Health category?<\/h3>\n
Is lapatinib still first-line?<\/h3>\n
Gerelateerde producten voor vrouwen gezondheid<\/h3>\n
\n
Gerelateerde alternatieven<\/h3>\n
\n
\n\u2705 Inhibits tumor growth
\n\u2705 Treats breast cancer
\n\u2705 Blocks HER2 receptors
\n\u2705 Verbetert overlevingskansen<\/p>\n